Senthil Lingaratnam

705 total citations
35 papers, 457 citations indexed

About

Senthil Lingaratnam is a scholar working on Oncology, Epidemiology and Clinical Biochemistry. According to data from OpenAlex, Senthil Lingaratnam has authored 35 papers receiving a total of 457 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 9 papers in Epidemiology and 8 papers in Clinical Biochemistry. Recurrent topics in Senthil Lingaratnam's work include Neutropenia and Cancer Infections (18 papers), Bacterial Identification and Susceptibility Testing (8 papers) and Pharmaceutical Practices and Patient Outcomes (4 papers). Senthil Lingaratnam is often cited by papers focused on Neutropenia and Cancer Infections (18 papers), Bacterial Identification and Susceptibility Testing (8 papers) and Pharmaceutical Practices and Patient Outcomes (4 papers). Senthil Lingaratnam collaborates with scholars based in Australia, United States and Netherlands. Senthil Lingaratnam's co-authors include Karin Thursky, Monica A. Slavin, Leon J. Worth, Sue Kirsa, Marliese Alexander, Linda Mileshkin, Danny Rischin, Kate Burbury, Benjamin W. Teh and Andrew H. Wei and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Critical Care.

In The Last Decade

Senthil Lingaratnam

35 papers receiving 446 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Senthil Lingaratnam Australia 13 253 141 123 78 51 35 457
Emily Mackler United States 10 224 0.9× 142 1.0× 51 0.4× 27 0.3× 82 1.6× 38 508
Ting‐Yi Chen United States 5 273 1.1× 239 1.7× 42 0.3× 47 0.6× 122 2.4× 5 742
Ruibin Wang United States 14 81 0.3× 94 0.7× 38 0.3× 124 1.6× 87 1.7× 35 485
Francisca M. Marti United Kingdom 5 307 1.2× 76 0.5× 131 1.1× 73 0.9× 23 0.5× 20 371
M.C. Ethier Canada 8 166 0.7× 132 0.9× 60 0.5× 50 0.6× 79 1.5× 8 365
Helene Skjøt‐Arkil Denmark 11 37 0.1× 138 1.0× 23 0.2× 33 0.4× 29 0.6× 51 512
Masamichi Yokoe Japan 22 414 1.6× 165 1.2× 34 0.3× 286 3.7× 50 1.0× 32 1.2k
Saurabh Chavan United States 6 78 0.3× 229 1.6× 24 0.2× 51 0.7× 32 0.6× 11 563
Danna Kurtin United States 8 139 0.5× 43 0.3× 55 0.4× 20 0.3× 67 1.3× 10 591
Per Engervall Sweden 15 304 1.2× 161 1.1× 196 1.6× 125 1.6× 46 0.9× 31 581

Countries citing papers authored by Senthil Lingaratnam

Since Specialization
Citations

This map shows the geographic impact of Senthil Lingaratnam's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Senthil Lingaratnam with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Senthil Lingaratnam more than expected).

Fields of papers citing papers by Senthil Lingaratnam

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Senthil Lingaratnam. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Senthil Lingaratnam. The network helps show where Senthil Lingaratnam may publish in the future.

Co-authorship network of co-authors of Senthil Lingaratnam

This figure shows the co-authorship network connecting the top 25 collaborators of Senthil Lingaratnam. A scholar is included among the top collaborators of Senthil Lingaratnam based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Senthil Lingaratnam. Senthil Lingaratnam is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Solomon, Benjamin, et al.. (2024). Utility of 30-Day Mortality Following Systemic Anti-Cancer Treatment as a Quality Indicator in Advanced Lung Cancer. Clinical Lung Cancer. 25(5). e211–e220.e1. 1 indexed citations
2.
Lingaratnam, Senthil, Benjamin Lee, Ian Campbell, et al.. (2024). Pharmacogenetic‐guided dosing for fluoropyrimidine (DPYD) and irinotecan (UGT1A1*28) chemotherapies for patients with cancer (PACIFIC‐PGx): A multicenter clinical trial. Clinical and Translational Science. 17(12). e70083–e70083. 1 indexed citations
3.
Krishnasamy, Mei, Senthil Lingaratnam, Sam Harris, et al.. (2023). Patient and healthcare professional acceptability of pharmacogenetic screening for DPYD and UGT1A1: A cross sectional survey. Clinical and Translational Science. 16(12). 2700–2708. 2 indexed citations
4.
Lingaratnam, Senthil, Mei Krishnasamy, Jennifer Martin, et al.. (2023). Pharmacogenetics testing (DPYD and UGT1A1) for fluoropyrimidine and irinotecan in routine clinical care: Perspectives of medical oncologists and oncology pharmacists. Journal of Oncology Pharmacy Practice. 30(1). 30–37. 6 indexed citations
5.
Alexander, Marliese, Smaro Lazarakis, Jennifer Martin, et al.. (2022). A systematic review and meta-analysis of toxicity and treatment outcomes with pharmacogenetic-guided dosing compared to standard of care BSA-based fluoropyrimidine dosing. British Journal of Cancer. 127(1). 126–136. 14 indexed citations
6.
Lee, Benjamin, Marliese Alexander, Danny Rischin, et al.. (2021). Feasibility of implementing a pharmacist-led DPYD gene testing service for patients commencing 5-fluorouracil (5FU) or capecitabine.. Journal of Clinical Oncology. 39(15_suppl). e18644–e18644. 2 indexed citations
7.
Alexander, Marliese, et al.. (2020). Cancer patients’ perspectives on participating in a community pharmacy-based hyperglycaemia screening service – A qualitative exploration of enablers and barriers. Research in Social and Administrative Pharmacy. 17(3). 613–618. 1 indexed citations
8.
Alexander, Marliese, et al.. (2019). Radiation oncology outpatient medication management needs and service gaps – A cross-sectional study of patients and clinicians. Journal of Oncology Pharmacy Practice. 26(4). 846–852. 3 indexed citations
9.
Thursky, Karin, Senthil Lingaratnam, Gabrielle M. Haeusler, et al.. (2018). Implementation of a whole of hospital sepsis clinical pathway in a cancer hospital: impact on sepsis management, outcomes and costs. BMJ Open Quality. 7(3). e000355–e000355. 41 indexed citations
10.
Lingaratnam, Senthil, et al.. (2016). Oral pristinamycin for the treatment of resistant Gram-positive infections in patients with cancer: Evaluation of clinical outcomes. International Journal of Antimicrobial Agents. 47(5). 391–396. 5 indexed citations
11.
12.
Lingaratnam, Senthil, et al.. (2013). Developing a Performance Data Suite to Facilitate Lean Improvement in a Chemotherapy Day Unit. Journal of Oncology Practice. 9(4). e115–e121. 20 indexed citations
13.
Alexander, Marliese, et al.. (2012). Thromboprophylaxis prescribing and thrombotic event rates in multiple myeloma patients treated with lenalidomide or thalidomide at a specialist cancer hospital. Asia-Pacific Journal of Clinical Oncology. 9(2). 169–175. 8 indexed citations
14.
Lingaratnam, Senthil, Monica A. Slavin, Bogda Koczwara, et al.. (2011). Introduction to the Australian consensus guidelines for the management of neutropenic fever in adult cancer patients, 2010/2011. Internal Medicine Journal. 41(1b). 75–81. 29 indexed citations
15.
Slavin, Monica A., Senthil Lingaratnam, Linda Mileshkin, et al.. (2011). Use of antibacterial prophylaxis for patients with neutropenia. Internal Medicine Journal. 41(1b). 102–109. 41 indexed citations
16.
Lingaratnam, Senthil, Leon J. Worth, Monica A. Slavin, et al.. (2011). A cost analysis of febrile neutropenia management in Australia: ambulatory v. in-hospital treatment. Australian Health Review. 35(4). 491–500. 16 indexed citations
17.
Lingaratnam, Senthil, Sue Kirsa, James D Mellor, et al.. (2011). A survey of reimbursement practices of private health insurance companies for pharmaceuticals not covered under the Pharmaceutical Benefits Scheme 2008. Australian Health Review. 35(2). 204–210. 1 indexed citations
18.
Tam, Constantine S., Małgorzata M. O’Reilly, David Andresen, et al.. (2011). Use of empiric antimicrobial therapy in neutropenic fever. Internal Medicine Journal. 41(1b). 90–101. 54 indexed citations
19.
Worth, Leon J., Senthil Lingaratnam, Anita Taylor, et al.. (2011). Use of risk stratification to guide ambulatory management of neutropenic fever. Internal Medicine Journal. 41(1b). 82–89. 24 indexed citations
20.
Lingaratnam, Senthil, Monica A. Slavin, Linda Mileshkin, et al.. (2011). An Australian survey of clinical practices in management of neutropenic fever in adult cancer patients 2009. Internal Medicine Journal. 41(1b). 110–120. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Emily Mackler Breakdown of academic impact, for papers by Ting‐Yi Chen Breakdown of academic impact, for papers by Ruibin Wang Breakdown of academic impact, for papers by Francisca M. Marti Breakdown of academic impact, for papers by M.C. Ethier Breakdown of academic impact, for papers by Helene Skjøt‐Arkil Breakdown of academic impact, for papers by Masamichi Yokoe Breakdown of academic impact, for papers by Saurabh Chavan Breakdown of academic impact, for papers by Danna Kurtin Breakdown of academic impact, for papers by Per Engervall
Rankless by CCL
2026